-
Mashup Score: 0Apellis and Sobi come unstuck in ALS - 11 month(s) ago
US biopharma Apellis Pharmaceuticals and Swedish Orphan Biovitrum, also known as Sobi, have become the latest to discover the difficulty of drug development in
Source: www.thepharmaletter.comCategories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 3Sanofi vWD therapy demonstrates significant potential of pipeline - 12 month(s) ago
Sanofi vWD therapy demonstrates significant potential of pipeline
Source: www.thepharmaletter.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0uniQure licenses gene therapy from Apic Bio - 1 year(s) ago
uniQure licenses gene therapy from Apic Bio
Source: www.thepharmaletter.comCategories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 1
German pharma major Boehringer Ingelheim and US tech-based therapy firm Click Therapeutics have announced the launch of an expanded collaboration on a second pr
Source: www.thepharmaletter.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0US FDA grants Fast Track status to BrainStorm Cell Therapeutics for ALS treatment NurOwn - 1 year(s) ago
The US Food and Drug Administration has designated a product from stem cell treatment developer BrainStorm Cell Therapeutics (Nasdaq: BCLI) as a Fast Track prod
Source: www.thepharmaletter.comCategories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 7
Indonesia’s PT BioFarma ready to produce IndoVac Covid-19 vaccine
Source: www.thepharmaletter.comCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 5
FDA accepts efanesoctocog alfa BLA for priority review for people with hemophilia A
Source: www.thepharmaletter.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
The US Food and Drug Administration (FDA) has unveiled an Action Plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis (ALS).
Source: www.thepharmaletter.comCategories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 27
Biological E has place in India’s COVID-19 vaccine market following Corbevax’ approval
Source: www.thepharmaletter.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0FDA puts partial hold on Foghorn’s Phase I study of FHD-286 - 2 year(s) ago
FDA puts partial hold on Foghorn’s Phase I study of FHD-286
Source: www.thepharmaletter.comCategories: Hem/Oncs, Latest HeadlinesTweet
https://t.co/YchloTbGZe